Search Results

March 16, 2026

From preparedness to recovery: New trainings for nurses responding to natural disasters

With support from the J&J Foundation, Sigma Theta Tau International Honor Society of Nursing launches a free, accredited training to equip nurses with the skills and support they need before, during and after crises.

Innovative Medicine

March 13, 2026

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate‑risk non–muscle-invasive bladder cancer

· Data presented at EAU 2026 show an 89 percent complete response rate in intermediate‑risk disease with durable responses observed over 18 months and tolerable safety profile · Erda-iDRS has the potential to be the first targeted treatment for early‑stage bladder cancer

Innovation

March 13, 2026

5 things we now know about plaque psoriasis

Plaque psoriasis is the most prevalent form of psoriasis, affecting millions worldwide. Johnson & Johnson is focused on developing novel therapies for chronic dermatologic diseases to address the unmet need that still exists.

March 12, 2026

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

• 97% of patients reported no very bothersome visual disturbances, like halos or glare, with TECNIS PureSee IOL1 • 97% of patients would recommend this IOL to friends or family2 • TECNIS PureSee IOL is the first and only U.S. FDA-approved extended depth of focus (EDOF) IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL1*

Innovative Medicine

March 10, 2026

TECVAYLI®▼ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 Teclistamab monotherapy delivered superior progression-free survival and overall survival versus standard of care, reducing the risk of disease progression or death by 71% in a high unmet need patient population2

Innovative Medicine

March 9, 2026

European Commission approves AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall survival versus standard of care1 Approximately one in ten patients with mHSPC harbour BRCA1/2 alterations, reinforcing the need for new targeted treatment options2 Expanded indication for niraparib and abiraterone acetate delivers a precision-based treatment approach for this patient population1

Innovative Medicine

March 5, 2026

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression‑free survival and overall survival versus standard of care regimens 83.3% of patients were alive at three years, indicating durable clinical benefit

Innovation

March 4, 2026

Getting in front of cancer

Every year, roughly 2 million people in the U.S. are newly diagnosed with cancer. But new scientific breakthroughs—including ones made at Johnson & Johnson—have dramatically changed the prognosis of many of these patients.

Innovative Medicine

March 3, 2026

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported by a Phase 2 study in which nipocalimab demonstrated reduction in lupus disease activity and potential for steroid sparing Systemic lupus erythematosus is a debilitating, chronic autoantibody-driven disease affecting multiple organs, with limited treatment options and risk of irreversible organ damage Johnson & Johnson is actively enrolling patients in a Phase 3 study of adults with active systemic lupus erythematosus

March 2, 2026

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Search Results

No Results

Search Results